X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs NOVARTIS - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH NOVARTIS STERLING BIOTECH/
NOVARTIS
 
P/E (TTM) x -0.4 290.4 - View Chart
P/BV x 0.0 32.2 0.0% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 STERLING BIOTECH   NOVARTIS
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
NOVARTIS
Mar-18
STERLING BIOTECH/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs11758 1.4%   
Low Rs3579 0.6%   
Sales per share (Unadj.) Rs26.8228.4 11.7%  
Earnings per share (Unadj.) Rs-15.031.7 -47.1%  
Cash flow per share (Unadj.) Rs-5.532.8 -16.7%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs54.9297.1 18.5%  
Shares outstanding (eoy) m267.8724.69 1,084.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 8.9%   
Avg P/E ratio x-0.521.1 -2.2%  
P/CF ratio (eoy) x-1.320.4 -6.2%  
Price / Book Value ratio x0.12.2 5.6%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m1,86216,505 11.3%   
No. of employees `0001.40.7 202.7%   
Total wages/salary Rs m5471,445 37.8%   
Avg. sales/employee Rs Th5,303.38,441.3 62.8%   
Avg. wages/employee Rs Th403.82,163.6 18.7%   
Avg. net profit/employee Rs Th-2,959.01,173.1 -252.2%   
INCOME DATA
Net Sales Rs m7,1815,639 127.3%  
Other income Rs m431,718 2.5%   
Total revenues Rs m7,2237,357 98.2%   
Gross profit Rs m947-63 -1,515.0%  
Depreciation Rs m2,54325 10,052.2%   
Interest Rs m4,37755 7,915.2%   
Profit before tax Rs m-5,9311,575 -376.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,924792 -243.1%   
Profit after tax Rs m-4,007784 -511.3%  
Gross profit margin %13.2-1.1 -1,189.7%  
Effective tax rate %32.450.3 64.6%   
Net profit margin %-55.813.9 -401.5%  
BALANCE SHEET DATA
Current assets Rs m14,3359,522 150.6%   
Current liabilities Rs m49,8093,296 1,511.2%   
Net working cap to sales %-494.0110.4 -447.5%  
Current ratio x0.32.9 10.0%  
Inventory Days Days40337 1,101.7%  
Debtors Days Days17128 600.4%  
Net fixed assets Rs m55,43246 120,505.0%   
Share capital Rs m268123 217.1%   
"Free" reserves Rs m13,9357,213 193.2%   
Net worth Rs m14,7017,336 200.4%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98811,105 666.2%  
Interest coverage x-0.429.5 -1.2%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.10.5 19.1%   
Return on assets %0.57.6 6.6%  
Return on equity %-27.310.7 -255.2%  
Return on capital %-6.422.2 -28.9%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86061 3,069.0%   
Fx outflow Rs m253,630 0.7%   
Net fx Rs m1,835-3,570 -51.4%   
CASH FLOW
From Operations Rs m1,7191,610 106.8%  
From Investments Rs m-3,148687 -458.3%  
From Financial Activity Rs m1,426-2,677 -53.3%  
Net Cashflow Rs m-3-380 0.9%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 2.0 -  
FIIs % 9.9 1.6 618.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 21.5 182.8%  
Shareholders   21,482 41,647 51.6%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS